IBJNews

Potential Lilly drug doubles good cholesterol

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.

Good cholesterol, or HDL, sweeps the bad form of the fatty substance, known as LDL, out of arteries, reducing clogs. The treatment being developed by Indianapolis-based Lilly, evacetrapib, boosted HDL by as much as 129 percent and lowered bad cholesterol as much as 36 percent, the research found.

The data, reported at the American Heart Association meeting Tuesday in Orlando, Fla., were similar to those seen last year with a rival from Merck & Co., called anacetrapib, researchers at the conference said. The Lilly trial is in the second of three phases of testing generally required for U.S. approval.

The Merck and Roche products are in the final stage. Both drugs are predicted to be blockbusters with more than $5 billion in annual sales if they are approved.

“We got everything we could hope for from this drug, and maybe more,” said Steven Nissen, the study’s senior author and chief of cardiology at the Cleveland Clinic in Ohio, in a telephone interview. “We are going to move evacetrapib forward as rapidly as possible” into a final-stage trial to prove it lowers heart risk.

Lilly shares were down 21 cents Tuesday morning, to $37.44 each.

All three rivals aim to avoid the toxicity seen with a previous good cholesterol drug from New York-based Pfizer Inc. that was abandoned in 2006 after it triggered deaths in a study.

Like the failed Pfizer drug, all three medicines boost good cholesterol by blocking a molecule called CETP. Unlike the Pfizer compound, Lilly’s drug didn’t raise blood pressure or levels of an adrenal hormone called aldosterone, the results show.

Lilly plans to meet with regulators “in the very near future” to discuss starting a final-stage trial as soon as possible, David Moller, a vice president for the company said. That trial would aim to show that the Lilly drug reduces heart attacks and cardiovascular deaths when given with standard cholesterol-lowering therapy.

“We feel we have a very competitive molecule,” he said. “This is a home-grown Lilly molecule that we diligently pursued under the radar of the public eye with the notion that we could get around” the problems seen with Pfizer’s torcetrapib.

The Lilly trial, in 398 patients, found that evacetrapib worked well combined with common cholesterol-lowering drugs such as Pfizer’s Lipitor, Crestor from London-based AstraZeneca Plc and simvastatin, the generic version of Merck’s Zocor.

If good cholesterol-raising treatments work, “it is going to revolutionize what we do,” said Christopher Cannon, a cardiologist at Brigham and Women’s Hospital in Boston, who has worked on Whitehouse Station, N.J.-based Merck’s compound. “If HDL means anything, these drugs should be amazing,” he said in an interview at the heart meeting.

Only giant trials in thousands of heart patients can prove if the CETP medicines really prevent heart attacks and deaths. Merck’s anacetrapib drug is in the process of being tested in a study of 30,000 heart patients.

“These could be as big as the statins were 20 years ago” if the data continues to be positive, Nissen said.

The promising Lilly results come as another marketed drug that modestly raises good cholesterol, Abbott Laboratories’ Niaspan, failed to show any benefit in reducing heart attacks and heart deaths when given with generic Zocor. The trial was stopped early by the National Institutes of Health in May because of lack of benefit and possible higher stroke risk.

Detailed results from the Niaspan research are also being presented at the heart meeting.

Patients on Niaspan, an extended release form of niacin, saw their HDL increase by 25 percent in the study versus just 9.8 percent HDL increase in those patients who received placebo. Yet the overall rate of heart attacks and several other cardiovascular events in both groups were virtually the same, the study found.

The higher number of strokes in patients who got Niaspan, a $927 million sales generator in 2010, weren’t statistically significant, said William Boden, a study investigator and professor at the University at Buffalo Schools of Medicine and Public Health.

“The clinical results were chillingly null,” wrote Robert Giugliano from Brigham and Women’s Hospital in an editorial accompanying the study in the New England Journal of Medicine.

For patients with stable heart disease whose bad cholesterol is under control, “there is no reason to prescribe niacin to raise low levels of HDL,” Boden said. Niacin still has a role in patients who can’t get their cholesterol under control with statin drugs, he said.
 

ADVERTISEMENT

  • other
    Vitamin C and lysine at the right levels can make those drugs unnecessary. Linus Pauling & Matthias have documented it.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Good Day I am Mr (Victoria Wright) from United state of America, i stayed in NEW YORK, and i have a broke up business, until i found this company email who help me to gain a loan for business,, and now i want to used this short medium to congratulate the below company for the fast and safe money they loan to me without any form of collateral, i loan 500,000USD from the company to save my business and lots more, i saw their mail on the internet, everyone always give testimony for what they did, so i quickly contacted them and they all did everything for me without stress and my money was sent to my account just 3 days later, i was surprise and i feel so glad, now i have a standard business control agent who help me, now i will advice those who need urgent loan to contact him at the bellow email:zenithfirm12@gmail.com

  2. NOTICE:This is to inform the general public that Vampires are real. My name is James Franklyn.,am an agent of vampire,am here to introduce our new world trend to you,a world of vampire where life get easier,we have made so many persons vampires and have turned them rich,you will be assured long life and prosperity,you shall be made to be very sensitive to mental alertness,stronger and also very fast,you will not be restricted to walking at night only even at the very middle of broad day light you will be made to walk.In case you are wildly oppressed by some unscrupulous persons we can still help you fight them.Your protection is assured immediately you join.Just contact the bellow email if you are interested we are here to attend to you anytime you want us. Contact the bellow email for more details. Email:vampirescreed@hotmail.com Sincerely: James Franklyn.

  3. Bravo! Someone else that is willing to speak the truth! Bravo!_____NBCSN is available in almost 2 MILLION more homes than just a few years ago, but Indycar STILL gets less total viewers than it did just a few years ago when NBC took over Versus. Attendance and ratings cratered with the end of season races (just when the title battle got "interesting" HAH!__________And now...new race in Basilia, where Miles celebrated the "rich history" of Indycar racing there. Rich history? What, 7 events in the 100 years of AOW? Yep, some history. Well, at least its an oval. It's not??? Are you kidding me??? Gosh darn road racin furriners.

  4. PURITY RAY LOAN OFFER........ Have you been denied by your banks,or are you in need of of an urgent loan to pay of your bills we are capable of giving loans @ cheaper rate to interested individuals, student, companies and members of the public in need of finance to settle bills, we do offer considerable loans which you can count on. For more information on our various types of loan,then you will have to contact PURITY RAY LOAN FIRM, to help you achieve your desire LOAN APPLICATION FORM TO BE FILLED BORROWERS INFORMATION * Full name:………………………. * SEX * ……………………………. * Country………………………….. * State:……………………………. * Land:…………………………….. * Occupation:…………………….. * phone number:…………………. * Telephone: ………………………….. * Age:………………………………. * Amount needed as loan:……… * Loan Duration:………………….. * Propose of Loan:……………….. * Annual revenue:………………… * Monthly Income:……………….. * Guarantee:………………………. * Payment: monthly or annually Email.....purityrayloanfirm@gmail.com Thank you and God bless Mr Purity Ray PURITY RAY LOAN FIRM we tend to serve you better

  5. Problem: most of the people responding to this article don't know about this service AT ALL! Why? Lack of awareness. This isn't IndyGo. This is CIRTA: might as well be the mattress company because they are asleep at the wheel - something like 3 directors over the last year? Playing with federal grant money is great! This "region" wants commuter rail service, has spent MILLIONS on Transportation studies yet can't even support a commuter bus line? This is largely for suburban riders to get to downtown - not for "service people to work in our hotels and restaurants" ! Get your head out of your backside!! These are professionals, students etc. that don't want to fight traffic, save some money on parking, gas, stress.... if CIRTA would put their federal money into widely promoting the sevive to Greenwood, Fishers & Carmel instead of finding directors and studies - this would be a successful service. Our family uses(d) it daily for the last several years - but the recent uncertainty & now unreliability due to cuts from Carmel has been a problem. Now, costs us an additional $350/month for gas & parking ( $4200/year) plus vehicle wear, service, environmental impact ... YES - this REGION needs this this type of service in order to keep growing and getting the people it needs to fill skilled positions in downtown Indianapolis. Think outside of your own car !!!

ADVERTISEMENT